KR102779525B1 - 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 - Google Patents

폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 Download PDF

Info

Publication number
KR102779525B1
KR102779525B1 KR1020177035856A KR20177035856A KR102779525B1 KR 102779525 B1 KR102779525 B1 KR 102779525B1 KR 1020177035856 A KR1020177035856 A KR 1020177035856A KR 20177035856 A KR20177035856 A KR 20177035856A KR 102779525 B1 KR102779525 B1 KR 102779525B1
Authority
KR
South Korea
Prior art keywords
polynucleotide
delete delete
composition
cancer
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177035856A
Other languages
English (en)
Korean (ko)
Other versions
KR20180021700A (ko
Inventor
크리스티아나 귀두치
로버트 엘. 코프만
Original Assignee
다이나박스 테크놀로지 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이나박스 테크놀로지 코퍼레이션 filed Critical 다이나박스 테크놀로지 코퍼레이션
Publication of KR20180021700A publication Critical patent/KR20180021700A/ko
Application granted granted Critical
Publication of KR102779525B1 publication Critical patent/KR102779525B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177035856A 2015-05-29 2016-05-23 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 Active KR102779525B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562168470P 2015-05-29 2015-05-29
US62/168,470 2015-05-29
US62/168,449 2015-05-29
US201562169321P 2015-06-01 2015-06-01
US201562169309P 2015-06-01 2015-06-01
US62/169,309 2015-06-01
US62/169,321 2015-06-01
US201662276767P 2016-01-08 2016-01-08
US62/276,767 2016-01-08
PCT/US2016/033817 WO2016196062A1 (en) 2015-05-29 2016-05-23 Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Publications (2)

Publication Number Publication Date
KR20180021700A KR20180021700A (ko) 2018-03-05
KR102779525B1 true KR102779525B1 (ko) 2025-03-12

Family

ID=56098419

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035856A Active KR102779525B1 (ko) 2015-05-29 2016-05-23 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여

Country Status (14)

Country Link
US (3) US9993495B2 (enExample)
EP (2) EP3590518B1 (enExample)
JP (1) JP6792294B2 (enExample)
KR (1) KR102779525B1 (enExample)
CN (1) CN107708706A (enExample)
AU (1) AU2016270782B2 (enExample)
CA (1) CA2987237A1 (enExample)
DK (1) DK3302502T3 (enExample)
ES (2) ES2987696T3 (enExample)
HK (1) HK1251471A1 (enExample)
IL (1) IL255903B (enExample)
MX (1) MX381587B (enExample)
RU (1) RU2017145940A (enExample)
WO (1) WO2016196062A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
MX391478B (es) 2014-10-10 2025-03-21 Idera Pharmaceuticals Inc Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer.
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
ES2987696T3 (es) 2015-05-29 2024-11-15 Dynavax Tech Corp Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018053242A1 (en) 2016-09-15 2018-03-22 Idera Pharmaceuticals, Inc. Immune modulation with tlr9 agonists for cancer treatment
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
WO2020079185A1 (en) * 2018-10-18 2020-04-23 Deutsches Krebsforschungszentrum Dry pharmaceutical composition for inhalation
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
WO2020128893A1 (en) * 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
TWI833056B (zh) * 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
EP4267136A4 (en) * 2020-12-23 2025-02-05 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
WO2023081486A1 (en) 2021-11-08 2023-05-11 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
AU2023209887A1 (en) * 2022-01-21 2024-08-15 Trisalus Life Sciences, Inc. Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058179A2 (en) 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN101134046A (zh) 2006-09-01 2008-03-05 中国医学科学院药物研究所 Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用
US20100184834A1 (en) 2002-12-23 2010-07-22 Dino Dina Immunostimulatory sequence oligonucleotides and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
AU2002231336B2 (en) 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
TW200533750A (en) * 2004-02-19 2005-10-16 Coley Pharm Group Inc Immunostimulatory viral RNA oligonucleotides
BRPI1008063A2 (pt) * 2009-01-30 2015-08-25 Idera Pharmaceuticals Inc Agonistas sinteticas de tlr9
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
ES2987696T3 (es) 2015-05-29 2024-11-15 Dynavax Tech Corp Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón
BR112017025533A2 (pt) * 2015-05-29 2018-08-07 Dynavax Tech Corp método para tratar câncer em um paciente humano
AU2017250348A1 (en) * 2016-04-15 2018-10-11 Dynavax Technologies Corporation Intratumoral administration of particles containing a Toll-like receptor 9 agonist and a tumor antigen for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058179A2 (en) 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US20100184834A1 (en) 2002-12-23 2010-07-22 Dino Dina Immunostimulatory sequence oligonucleotides and methods of using the same
CN101134046A (zh) 2006-09-01 2008-03-05 中国医学科学院药物研究所 Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用

Also Published As

Publication number Publication date
KR20180021700A (ko) 2018-03-05
AU2016270782A1 (en) 2017-12-07
WO2016196062A1 (en) 2016-12-08
US10369168B2 (en) 2019-08-06
US9993495B2 (en) 2018-06-12
US20190151345A1 (en) 2019-05-23
EP3590518A1 (en) 2020-01-08
CA2987237A1 (en) 2016-12-08
MX381587B (es) 2025-03-12
EP3590518B1 (en) 2024-03-20
ES2752063T3 (es) 2020-04-02
IL255903A (en) 2018-01-31
CN107708706A (zh) 2018-02-16
NZ737488A (en) 2024-12-20
RU2017145940A3 (enExample) 2019-11-26
HK1251471A1 (zh) 2019-02-01
US20180264023A1 (en) 2018-09-20
ES2987696T3 (es) 2024-11-15
US10111899B2 (en) 2018-10-30
EP3302502A1 (en) 2018-04-11
AU2016270782B2 (en) 2021-08-12
DK3302502T3 (da) 2019-10-28
US20160346312A1 (en) 2016-12-01
JP2018521011A (ja) 2018-08-02
EP3302502B1 (en) 2019-08-28
JP6792294B2 (ja) 2020-11-25
RU2017145940A (ru) 2019-07-02
MX2017015294A (es) 2018-02-19
IL255903B (en) 2021-09-30

Similar Documents

Publication Publication Date Title
KR102779525B1 (ko) 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
AU2011329668B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP1934239B1 (en) Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
WO2017143449A1 (en) Smc combination therapy for the treatment of cancer
US20110171209A1 (en) Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9
KR20170100033A (ko) 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법
KR20190034210A (ko) 암 면역 아쥬반트
US20090098063A1 (en) Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
JP2023519413A (ja) 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用
KR20100126390A (ko) 톨-유사 수용체 3의 선택적인 작용제
JP6536964B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
US20210315991A1 (en) Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
HK40020378A (en) Polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
US20240115681A1 (en) Pharmaceutical composition comprising toll-like receptor agonist and stimulator of interferon genes agonist and use thereof
WO2024153142A1 (zh) CpG寡核苷酸及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601